glp 1 agonist mounjaro GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Mounjaro, Zepbound: Generic GLP-1 Drugs

Ozempic and Wegovy users focus on nausea and vomiting

Tirzepatide for dual receptor studies.

Accessing cheaper weight loss drugs involves compounding pharmacies, savings coupons, or cash-pay programs for people who cannot afford them.

CMS GLP-1 Bridge Program: Medicare Part D coverage for weight-loss GLP-1 drugs starting July 1, 2026, including eligibility, covered medications, prior authorization, and copay rules.

A comprehensive literature search was conducted across the PubMed, Embase, and Google Scholar databases for peer-reviewed articles published from inception through June 15, 2026, focusing on the landmark SURPASS, SURMOUNT, and SUMMIT trial programs, relevant cardiorenal post hoc analyses, emerging body recomposition trials, and real-world cohort-switching protocols